Open AccessPre admission treatment with Beta‐blockers in hypertensive patients with acute stroke and 3‐month outcome—Data from a national stroke registry
Author(s) -
Eizenberg Yoav,
Grossman Ehud,
Tanne David,
Koton Silvia
Publication year - 2018
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.13211
Subject(s) - medicine , stroke (engine) , atrial fibrillation , intracerebral hemorrhage , odds ratio , barthel index , acute stroke , physical therapy , activities of daily living , subarachnoid hemorrhage , mechanical engineering , tissue plasminogen activator , engineering
The impact of beta‐blockers ( BB ) treatment on stroke outcome is unclear. We used data from a prospective national stroke registry to assess the associations between use of BB and poor outcome 3 months after stroke. Using the National Acute Stroke Israeli ( NASIS ) registry, we identified 1126 patients with ischemic stroke and intracerebral hemorrhage with pre‐stroke hypertension treatment, who were followed for 3‐months. Functional outcome and mortality at 3‐month were compared by use of BB , adjusting for demographics and clinical factors. Pre‐stroke use of BB was reported by 615 (54.6%) patients. Users of BB showed higher rates of atrial fibrillation, heart disease, statin use, cancer, and severe stroke. Adjusted odds‐ratios ( OR s, 95% CI ) for BB users compared with non‐users 3 months after stroke were 0.86 (0.49‐1.52) for mortality and 1.07 (0.76‐1.50) for Barthel Index ≤60. In conclusion, treatment with BB is not associated with 3‐month poor outcome in hypertensive patients.